London, United Kingdom – At the 41st Annual European Association of Urology (EAU) Congress, currently underway in London, Italian medical imaging firm Esaote Group is showcasing advancements in diagnostic technology aimed at improving precision in urological care. Central to their presentation is the Prostate Attention Map (PAM) technology, a modern innovation designed to assist clinicians in the detection and targeted treatment of prostate cancer. The EAU Congress, running from March 13-16, 2026, serves as a key platform for Esaote to demonstrate its commitment to providing advanced imaging and guided therapy solutions for urologists worldwide.
The increasing incidence of prostate cancer globally underscores the critical require for more accurate and efficient diagnostic tools. Traditional methods, while effective, can sometimes lead to unnecessary biopsies and delayed treatment. Esaote’s PAM technology, integrated into their UroFusion software and available on the MyLab™E85 GTS, aims to address these challenges by offering automated analysis of prostate mpMRI volumes and identifying suspicious regions of interest. This technology promises to enhance target guidance and ultimately improve clinical decision-making for urologists. The company is also presenting the new MyLab™C30 GTS ultrasound system, emphasizing portability without compromising image quality, catering to diverse examination settings.
Advancing Prostate Cancer Detection with PAM Technology
The core innovation presented by Esaote at EAU 2026 is the Prostate Attention Map (PAM) technology. PAM leverages artificial intelligence to analyze multi-parametric MRI (mpMRI) scans of the prostate, automatically identifying areas that warrant closer examination. According to Marta Daniel, Guided Therapy Product and Clinical Solutions Manager at Esaote, the technology is “fully integrated into Esaote’s UroFusion software,” designed to provide focal guidance during prostate targeted biopsies. This integration streamlines the workflow for clinicians, potentially reducing the time required for biopsies while simultaneously increasing confidence and accuracy. The goal is to minimize unnecessary interventions and ensure that treatment is focused on areas of genuine concern.
The development of PAM technology reflects a broader trend in medical imaging towards AI-assisted diagnostics. By automating the analysis of complex imaging data, AI can help radiologists and urologists identify subtle patterns and anomalies that might be missed by the human eye. This can lead to earlier and more accurate diagnoses, ultimately improving patient outcomes. Esaote’s approach focuses specifically on the unique challenges of prostate cancer detection, aiming to provide a tailored solution for clinicians in this field. The company emphasizes that PAM is not intended to replace the expertise of medical professionals but rather to augment their capabilities and enhance their decision-making process.
MyLab™C30 GTS: Portable Ultrasound with High-Performance Imaging
Alongside the PAM technology, Esaote is also showcasing the MyLab™C30 GTS, a new portable ultrasound system designed to deliver high-quality imaging in a variety of clinical settings. The MyLab™C30 GTS is engineered to meet the demands of prompt ultrasound access, versatility, and space constraints. According to Esaote’s website, the system shares advanced imaging technologies and transducers with their high-end systems, ensuring high-quality images and clinical information despite its compact size. The MyLab™C30 features a tiltable 15.6” main screen and an ultrawide touchscreen with digital TGC for ease of employ. The system’s portability makes it particularly well-suited for use in outpatient clinics, remote locations, and point-of-care settings.
The introduction of the MyLab™C30 GTS underscores Esaote’s commitment to providing clinicians with flexible and adaptable imaging solutions. The ability to deliver high-quality ultrasound imaging in a portable format can significantly improve access to care, particularly in underserved communities or in situations where traditional imaging facilities are not readily available. The system’s intuitive interface and advanced imaging capabilities are designed to empower clinicians to make informed decisions quickly and efficiently.
Esaote’s Comprehensive Urological Portfolio and Hands-on Training
At the EAU 2026 Congress, Esaote (Booth N16) is presenting a comprehensive portfolio of solutions designed to support diagnosis precision and intervention guidance in prostate care. This includes not only the PAM technology and the MyLab™C30 GTS but also a range of other imaging and software tools. The company is actively participating in TP Biopsy and MRI-US Fusion practical training sessions led by internationally recognized experts, allowing attendees to experience the latest advancements in UroFusion technology firsthand. These hands-on sessions provide clinicians with the opportunity to learn how to effectively integrate these tools into their clinical practice and improve patient care.
Esaote’s commitment to education and training is a key component of its overall strategy. By providing clinicians with the knowledge and skills they need to effectively utilize these advanced technologies, the company aims to drive innovation and improve outcomes in the field of urology. The practical training sessions at EAU 2026 are a testament to this commitment, offering attendees a valuable opportunity to learn from leading experts and gain hands-on experience with the latest imaging and guidance tools.
Expanding Guided Therapy Solutions and Future Outlook
The launch of PAM technology and the introduction of the MyLab™C30 GTS represent a significant expansion of Esaote’s Guided Therapy Solutions (GTS) line. This expansion reflects the company’s broader strategy of providing intelligent clinical imaging solutions that support clinicians throughout the entire patient care pathway. Esaote’s commitment to innovation in this area is driven by a desire to provide urologists with the tools they need to deliver reliable, efficient, and clinically excellent care. The company’s focus on advanced imaging quality, intuitive user interfaces, and seamless image fusion workflows underscores its dedication to improving the diagnostic and therapeutic process for both clinicians and patients.
Esaote Group, headquartered in Genoa, Italy, is a global player in the medical imaging sector, specializing in ultrasound, MRI, and diagnostic process management software. As of late 2025, the company employs approximately 1,300 people, with half of its workforce based in Italy. Esaote operates production and research facilities in Italy and the Netherlands and currently conducts business in over 100 countries worldwide. More information about Esaote can be found on their official website.
Looking ahead, Esaote is poised to continue its leadership in the field of medical imaging, with a particular focus on developing innovative solutions for urological care. The company’s ongoing investment in research and development, coupled with its commitment to collaboration with clinicians and researchers, will undoubtedly lead to further advancements in diagnostic and therapeutic technologies. The next key milestone for Esaote will be the continued rollout of PAM technology and the expansion of its GTS line to address the evolving needs of urologists around the globe.
The company will continue to present data and updates on PAM technology and its clinical applications at upcoming medical conferences and through peer-reviewed publications. Readers interested in learning more about Esaote’s innovations are encouraged to visit their website and follow their updates on social media. Share your thoughts on the potential impact of AI-powered diagnostic tools in the comments below.